• Biomolecules & Therapeutics
• /
• 제7권3호
• /
• pp.278-284
• /
• 1999

DK1001 is a thebain derivative, which is newly synthesized as an alkaloid analgesic. This study was designed to study effects of DK1001 on the ligands binding to the opioid receptor subtypes, and general pharmacology of DK1001. DK1001 inhibited the binding of [$^3H$]DAMGO, a selective mu-subtype agonist, to the opioid receptor of rat forebrain in a concentration-dependent manner. $EC_{50}$ of DK1001 was significantly lower than that of morphine. DK1001 inhibited the binding of 〔$^3$H〕DPDPE, a selective delta-subtype agonist concentration-dependently. DK1001(0.5 mg/kg) had no effects on behavior, body temperature, blood pressure. respiratory rate, and intestinal charcoal propulsion of mice. In addition, DK1001 did not affect on the contractilities of isolated muscle strips of aorta, ileum, and trachea of rats. These results suggest that DK1001 might be a potent analgesic without serious side effects.

• 한국항공우주학회지
• /
• 제42권12호
• /
• pp.1065-1072
• /
• 2014

우주용 GPS 수신기에 널리 사용되었으나 단종된 GP2021 소자를 대체하기 위해, GPS 디지털 신호 처리부인 SIGP-1001을 개발하였다. GP2021 소자와 동일한 운용조건에서 수행한 각종 실험을 통해 SIGP-1001의 성능이 GP2021 소자의 성능과 유사함을 확인하였고, 그 결과 SIGP-1001으로 GP2021 소자를 충분히 대체 가능한 것으로 판단하였다. FPGA IP(Field Programmable Gate Array Intellectual Property) 형태로 개발한 SIGP-1001을 우주급 FPGA에 적용하면 GP2021 소자를 사용하였을 경우에 비해 신뢰성 향상이 가능하며, 위성 추적 채널 수 추가 등의 기능 확장을 통한 성능 개선이 가능하다.

• 대한약침학회지
• /
• 제11권2호
• /
• pp.41-53
• /
• 2008

Objective&Methods The purpose of this study is to observe the effects of HK-1001 Pharmacopuncture at GB34(Yangleungchean) on hyperlipidemia in rats. The author performed several experimental items to analyze the levels of various components and enzymes in serum, urine and liver, as well as the histological changes of liver and aorta. Results 1. HK-1001 Pharmacopuncture infusion solution increased the cell viability rate, DPPH radical scavenging activity and HMG-CoA reductase inhibition rate in rat liver cells. 2. The levels of total cholesterol, free cholesterol, LDL-cholesterol, phospholipid in serum and AI(atherogenic index) were decreased, and the ratio of HDL to TCL(HDL/TCL) and the level of TG in serum were increased as compared with those of the control group. 3. In the HK-1001 group, serum GOT was significantly lower than those of the HG group and the saline group, and serum ALP was significantly higher than that of the HG group. 4. Hepatic GSH and catalase activities were significantly increased as compared with those of the saline group. Conclusion From the above results, it is suggested that HK-1001 Pharmacopuncture at GB34 has a therapeutic effect on hyperlipidemia.

• 한국축산식품학회지
• /
• 제44권4호
• /
• pp.951-965
• /
• 2024

Lactiplantibacillus plantarum is a valuable potential probiotic species with various proven health-beneficial effects. L. plantarum LM1001 strain was selected among ten strains of L. plantarum based on proteolytic activity on whey proteins. L. plantarum LM1001 produced higher concentrations of total free amino acids and branched-chain amino acids (Ile, Leu, and Val) than other L. plantarum strains. Treatment of C2C12 myotubes with whey protein culture supernatant (1%, 2% and 3%, v/v) using L. plantarum LM1001 significantly increased the expression of myogenic regulatory factors, such as Myf-5, MyoD, and myogenin, reflecting the promotion of myotubes formation (p<0.05). L. plantarum LM1001 displayed β-galactosidase activity but did not produce harmful β-glucuronidase. Thus, the intake of whey protein together with L. plantarum LM1001 has the potential to aid protein digestion and utilization.

• 미생물학회지
• /
• 제54권1호
• /
• pp.71-73
• /
• 2018

최근 Fusobacterium nucleatum subsp. polymorphum는 average nucleotide identity 및 genome-to-genome distance 분석법에 의해 Fusobacterium polymorphum로 재분류 되었다. F. polymorphum 그람 음성이면서, 혐기성 및 가는 섬유 모양의 세균이다. F. polymorphum은 사람의 구강 내 정상세균총의 하나이고, 치주질환의 원인 인자이다. F. polymorphum KCOM 1001 (= ChDC F119) 균주가 사람 치은염 병소의 치은연하치면세균막에서 분리되었다. F. polymorphum KCOM 1001 균주 유전체 염기서열을 해독하여 보고한다.

• 대한치매학회지
• /
• 제22권3호
• /
• pp.100-108
• /
• 2023

Background and Purpose: The efficacy and safety of GV1001 have been demonstrated in patients with moderate-to-severe Alzheimer's disease (AD). In this study, we aimed to further demonstrate the effectiveness of GV1001 using subscales of the Severe Impairment Battery (SIB), which is a validated measure to assess cognitive function in patients with moderate-to-severe AD. Methods: We performed a post hoc analysis of data from a 6 month, multicenter, phase 2, randomized, double-blind, placebo-controlled trial with GV1001 (ClinicalTrials.gov, NCT03184467). Patients were randomized to receive either GV1001 or a placebo for 24 weeks. In the current study, nine subscales of SIB-social interaction, memory, orientation, language, attention, praxis, visuospatial ability, construction, and orientation to name-were compared between the treatment (GV1001 1.12 mg) and placebo groups at weeks 12 and 24. The safety endpoints for these patients were also determined based on adverse events. Results: In addition to the considerable beneficial effect of GV1001 on the SIB total score, GV1001 1.12 mg showed the most significant effect on language function at 24 weeks compared to placebo in both the full analysis set (FAS) and per-protocol set (PPS) (p=0.017 and p=0.011, respectively). The rate of adverse events did not differ significantly between the 2 groups. Conclusions: Patients with moderate-to-severe AD receiving GV1001 had greater language benefits than those receiving placebo, as measured using the SIB language subscale.

• 대한치과의사협회지
• /
• 제28권12호통권259호
• /
• pp.1001-1001
• /
• 1990

• 한국환경과학회:학술대회논문집
• /
• 한국환경과학회 1993년도 가을 학술발표회 초록집
• /
• pp.1001-1001
• /
• 1993

• 대한치과의사협회지
• /
• 제22권12호통권187호
• /
• pp.1001-1001
• /
• 1984

• 대한치과의사협회지
• /
• 제23권12호통권199호
• /
• pp.1001-1001
• /
• 1985